Kamuvudine-9 is under clinical development by Inflammasome Therapeutics and currently in Phase I for Graves’ Ophthalmopathy. According to GlobalData, Phase I drugs for Graves’ Ophthalmopathy have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Kamuvudine-9’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Kamuvudine-9 overview
Kamuvudine-9 is under development for the treatment of Graves' ophthalmopathy (thyroid eye disease). It is administered through oral route. The drug candidate is a chemical derivative of nucleoside reverse transcriptase inhibitor (NRTI).
Inflammasome Therapeutics overview
Inflammasome Therapeutics is developing medicines for prevalent, degenerative diseases including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease and macular degeneration. The company is headquartered in Newton, Massachusetts, the US.
For a complete picture of Kamuvudine-9’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
